Condition: Dementia With Lewy Bodies · Sponsor: EIP Pharma Inc
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Barrow Neurological Institute | Phoenix, Arizona, United States | — |
| Banner Sun Health Research Institute | Sun City, Arizona, United States | — |
| Banner Alzheimer's Institute - Edson Family Lewy Body Dementia Center | Tucson, Arizona, United States | — |
| UCSD Health Sciences - Movement Disorders Center | La Jolla, California, United States | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | — |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | — |
| SC3 Research Group | Pasadena, California, United States | — |
| University of Colorado - Dept of Neurology | Aurora, Colorado, United States | — |
| Georgetown Univ Hospital - Dept of Neurology | Washington D.C., District of Columbia, United States | — |
| JEM Research Institute | Lake Worth, Florida, United States | — |
| ClinCloud | Melbourne, Florida, United States | — |
| AdventHealth Neuroscience Research | Orlando, Florida, United States | — |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05869669